Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis
- 14 April 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 281 (14) , 1275-1281
- https://doi.org/10.1001/jama.281.14.1275
Abstract
Research from JAMA — Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis — A Randomized Controlled Trial — ContextPatients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated.ObjectiveTo assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients.DesignRandomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997.SettingHospital-based outpatient dialysis unit.PatientsTwenty-nine patients undergoing dialysis for at least 3 months.InterventionNandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months.Main Outcome MeasuresWeight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment.ResultsLean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 {2.3} mg/dL]; P = .02) but not in the placebo group (−4.0 [177] mmol/L [0.04 {2.0} mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group.ConclusionsTreatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.Keywords
This publication has 22 references indexed in Scilit:
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal MenNew England Journal of Medicine, 1996
- Effect of Nutrition on Morbidity and Mortality in Maintenance Dialysis PatientsAmerican Journal of Kidney Diseases, 1994
- Short-term effects of recombinant human growth hormone in CAPD patientsKidney International, 1994
- Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormoneThe Journal of Pediatrics, 1993
- Total-Body Nitrogen by Neutron Activation in Maintenance DialysisAmerican Journal of Kidney Diseases, 1990
- Death Risk in Hemodialysis Patients: The Predictive Value of Commonly Measured Variables and an Evaluation of Death Rate Differences Between FacilitiesAmerican Journal of Kidney Diseases, 1990
- Diabetogenic Action of GH and Cortisol in Insulin-Dependent Diabetes Mellitus Aspects of the Mechanisms Behind the Somogyi PhenomenonHormone and Metabolic Research, 1987
- The Sickness Impact Profile: Development and Final Revision of a Health Status MeasureMedical Care, 1981
- CLINICAL EFFECTS OF ORAL FLUOXYMESTERONE IN PATIENTS WITH DIALYSIS-CONTROLLED UREMIAAsaio Journal, 1973
- Body Composition in Chronic Renal Failure1QJM: An International Journal of Medicine, 1972